Gregory N. Dietsch
Directeur Technique/Scientifique/R&D chez VentiRx Pharmaceuticals, Inc.
Profil
Gregory N.
Dietsch is currently the Vice President-Research at VentiRx Pharmaceuticals, Inc. and a Diplomat at the American Board of Toxicology.
He was previously the Vice President-Preclinical Sciences at ICOS Corp.
Dietsch holds a doctorate degree from Oregon Health & Science University and undergraduate and graduate degrees from Washington State University.
Postes actifs de Gregory N. Dietsch
| Sociétés | Poste | Début |
|---|---|---|
VentiRx Pharmaceuticals, Inc.
 VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Directeur Technique/Scientifique/R&D | - |
| American Board of Toxicology | Corporate Officer/Principal | - |
Anciens postes connus de Gregory N. Dietsch
| Sociétés | Poste | Fin |
|---|---|---|
ICOS Corp.
 ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Corporate Officer/Principal | - |
Formation de Gregory N. Dietsch
| Washington State University | Graduate Degree |
| Oregon Health & Science University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Health Technology |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Health Technology |
| American Board of Toxicology |
